Nkarta (NKTX) said Thursday it opened enrollment for the Ntrust-2 trial and received clearance to initiate an investigator-sponsored trial to evaluate its experimental therapy, NKX019, in patients with myasthenia gravis.
The company said Ntrust-2 is a study to assess NKX019 in patients with systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis.
The investigator-sponsored study would be led by researchers at the University of California, Irvine, and the University of Kansas Medical Center, the company said.
It added the trials will evaluate the therapy's safety and potential to induce long-term remission by eliminating pathogenic B cells.
Preliminary data from the studies are expected in 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。